MaxCyte Minutes Newsletter – Q2 2022
We have been very busy at MaxCyte for the last few months and are excited about the year ahead, we hope your research and projects are advancing in the same exciting way. Our MaxCyte minute newsletter is back with the intent to give you a snapshot of our progress, and content we believe can be relevant to you. As always, we welcome your feedback and will include a survey link at the end of each newsletter, feel free to comment!
IN THE NEWS
We were thrilled to announce Cenk Sumen, Ph.D. as MaxCyte’s new Chief Scientific Officer early March. With a proven track record of scientific, technological and business development expertise, Dr. Sumen brings experience in technology, application and platform assessments, the development of commercial partnerships and leading interdepartmental collaboration to accelerate scientific and technical direction.
CELL & GENE THERAPY
Featured Presentation from CAR TCR
We attended Next Generation CAR-TCR this year and were honored to be featured in Richard Horbottle’s presentation focusing on his work at DKFZ German Cancer Research Center on next-generation DNA NanoVectors.
Upcoming Webinar: A GMP Compatible, Non-Viral CAR T Cell Manufacturing Process
Join us for a Labroots Webinar on advances from scientists at the University of California San Francisco in non-viral CAR T cell manufacturing. Learn how the use of MaxcyteR ExpertTM technology platform helped achieve a highly efficient knock-in integration resulting in T cells modification in clinically relevant amounts.
Date: Tuesday May 24, 2022
Time: 9:00am (PDT), 12:00pm (EDT), 6:00pm (CEST)
The entire MaxCyte commercial team came together for a much overdue opportunity to connect and collaborate in person
To strengthen our commitment to patients, we were honored to have Emily Whitehead and Tom Whitehead from the Emily Whitehead Foundation as two of our distinguished guests. Sharing their story, passion, and energy was inspirational as we support our partners to develop and deliver more robust and accessible gene and cell therapies worldwide.
We celebrate Emily being 10 years cancer-free and will continue to work closely with the Emily Whitehead Foundation to support the patients following in her footsteps. MaxCyte is proud to be a sponsor of September’s Emily Whitehead Foundation Believe Ball, and look forward to witnessing the transformation of healthcare and the value that these innovative medicines will bring to patients.
Andrew Mancini, Field Applications Scientist
Andrew Mancini is a MaxCyte Field Applications Scientist, working closely with our partners around the world to develop novel cell engineering workflows for the development of cellular therapeutics. Having completed his PhD in Biomedical Sciences at the University of California, San Francisco and his postdoctoral training at Genentech in Molecular Oncology, Andrew has a broad range of experience and expertise that encompasses non-viral and viral engineering of primary immune cells, stem cells, and cell lines at both research and manufacturing scales.